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Abstract
c-CBL (CBL) encodes a member of the Cbl family of proteins, which functions as an E3 ubiquitin 
ligase. We describe a dominant developmental disorder resulting from germline missense CBL 
mutations, which is characterized by constitutional anomalies that include impaired growth, 
developmental delay, cryptorchidism, and a predisposition to juvenile myelomonocytic leukemia 
(JMML). Some individuals experienced spontaneous regression of their JMML but developed 
vasculitis later in life. Importantly, JMML specimens from affected children show loss of the 
normal CBL allele through acquired isodisomy. Consistent with these genetic data, the common 
p.Y371H mutant Cbl protein induces cytokine-independent growth and constitutive 
phosphorylation of ERK, AKT, and S6 only in hematopoietic cells in which normal Cbl 
expression is reduced by RNA interference. We conclude that germline CBL mutations have 
developmental, tumorigenic, and functional consequences that are reminiscent of disorders that are 
caused by hyperactive Ras/Raf/MEK/ERK signaling and include neurofibromatosis type 1, and 
Noonan, Costello, cardiofaciocutaneous, and Legius syndromes.
Myeloproliferative neoplasms (MPNs) are clonal malignancies characterized by 
overproduction of immature and mature myeloid lineage cells. In particular, juvenile 
myelomonocytic leukemia (JMML) is an aggressive MPN of childhood characterized by 
malignant transformation in the stem cell compartment with clonal proliferation of progeny 
that variably retain the capacity to differentiate (reviewed in 1). Hematopoietic stem cell 
transplantation (HSCT) is the only curative therapy for JMML; however, relapse rates 
approach 30% 2. While spontaneous remissions occur in some infants 3,4, the underlying 
mechanism for this is unknown.
Extensive molecular data implicate germline and somatic mutations that deregulate Ras 
signaling as key initiating events in JMML, with studies showing that 60% of patients 
harbor an oncogenic mutation in PTPN11, NRAS, or KRAS while another 15% have 
neurofibromatosis type 1 (NF1) and demonstrate loss of the normal NF1 allele in leukemic 
cells 5-9. Patients with the myeloproliferative subtype of chronic myelomonocytic leukemia 
(CMML), a similar MPN of adulthood, frequently acquire NRAS, KRAS, and JAK2 
mutations 10,11. Genetically accurate mouse models recapitulate these diseases, supporting 
the hypothesis that hyperactive Ras is necessary and sufficient to cause MPN 12-15. A 
hallmark feature of JMML and CMML is the formation of abnormally high numbers of 
granulocyte-macrophage colony-forming units (CFU-GM) in methylcellulose cultures 
containing low concentrations of GM-CSF 16,17. Phosphorylation of the βc chain of the GM-
CSF receptor creates docking sites for adapters and signal relay molecules, resulting in 
activation of the Ras pathway.
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Recently, we and others used high density single nucleotide polymorphism arrays to analyze 
blood and bone marrow specimens from patients with MPN 18-21. These studies revealed 
copy-neutral loss of heterozygosity (acquired isodisomy) of a region on chromosome 11q in 
some cases, and subsequent studies demonstrated homozygous mutations in CBL. 
Approximately 10-15% of children with de novo JMML are estimated to harbor 
homozygous CBL mutations20,22. CBL mutations are acquired somatically in adults with 
MPN 18,19,21.
Children with NF1 and Noonan syndrome (NS) are predisposed to JMML 8,9,23-25, and we 
therefore considered the possibility that germline CBL mutations occur in some affected 
children. A review of the medical records of the 21 children with JMML found to have CBL 
mutations enrolled in the EWOG-MDS studies or treated at USCF (16 of 21 were previously 
included in a screen of a larger international cohort20) uncovered an unexpectedly high 
percentage with developmental delay and other congenital anomalies, which included 
cryptorchidism, and impaired growth (Tables 1 and 2). All children met diagnostic criteria 
for JMML26,27 but six patients with a follow-up of more than seven years did not undergo 
transplantation for various reasons. Of these, one died of progressive JMML (D088), but the 
MPN improved spontaneously in five others. All of these patients continued to display 
variable degrees of splenomegaly in the presence of normal blood counts and exhibited the 
persistence of a homozygous CBL mutation in CD4, CD8, CD14, and CD19 sorted cells 
from their peripheral blood at last follow-up. In addition, four of these patients have 
developed clinical signs consistent with vascular pathology, including optic atrophy, 
hypertension, and an acquired cardiomyopathy; one was diagnosed with Takayasu arteritis, 
type III by angiography (Figure 1a). Another patient (D256) developed an intracranial 
germinoma harboring the same homozygous CBL mutation as in his bone marrow. Of note, 
among the patients treated with HSCT, there was a high rate of conversion to stable mixed 
chimerism (8/11 patients with available data) (Table 1).
We analyzed normal tissues from 17 of these children and detected a heterozygous CBL 
mutation in each. Mutational analysis of parental DNA was informative in 13 families and 
confirmed autosomal inheritance of a CBL mutation in seven (Figure 1b, 1c, Table 2, and 
Figure S1). Patients UPN1333 and UPN1125 were from large pedigrees in which several 
individuals had died of JMML (Figure 1b and c).
The proband in family 1 (UPN1333, V:1) (Figure 1a) was referred after transplantation for 
JMML. Initially diagnosed at 7 months of age, he received his first HSCT at age 13 months 
and then developed mixed chimerism 6 months later. A blood sample displayed a 
homozygous CBL mutation at c.1111T>C (Y371H). Importantly, analysis of buccal swab 
DNA revealed a heterozygous lesion. Both maternal relatives died from progressive JMML. 
Peripheral blood or buccal swabs from extended family members revealed multiple 
heterozygous individuals (Figure 1b). Interestingly, detailed medical history from the 
affected maternal great-grandmother revealed a history of infant leukemia characterized by a 
high white blood cell count and splenomegaly that resolved spontaneously. Sorted B (CD19) 
and T (CD3) cells, and granulocytes from her peripheral blood currently display a 
heterozygous c.1111T> C. Leukemia cells from UPN1333 displayed a classic pattern of 
GM-CSF hypersensitivity (Figure 1d) and increased phosphorylation of STAT5 in response 
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to low doses of GM-CSF 28. Peripheral blood mononuclear cells from his heterozygous 
mother did not display either of these features, suggesting that homozygosity for the mutant 
CBL allele is essential for these cellular behaviors (data not shown).
The proband in family 2 (UPN1125, IV:3) was a girl diagnosed at 15 months of age with 
JMML. She also harbored a homozygous c.1111T>C CBL mutation in her bone marrow. 
Family history revealed that her mother had two male first cousins who were diagnosed with 
JMML and died before age 10. The first boy had archived frozen liver tissue available from 
autopsy and demonstrated a heterozygous c.1111T>C mutation. Interestingly, he also 
developed clinical signs and laboratory values consistent with small vessel vasculitis prior to 
his death. Her mother of UPN1125 was found to carry a heterozygous CBL mutation (Figure 
1c).
Three patients in our series displayed homozygous splice site mutations (Table 2, I066, 
D647, and D347). RT-PCR demonstrated several new splice products arising from these 
mutations (Figure 2); most notable are the 2 splice site variants that either delete the entirety 
of exon 8 (D347) or exon 9 (I066 and D647) (Figure S2) or retain an interstitial intron (e.g. 
intron 7 for D347). Each of the deletion splice variants encodes a protein that is predicted to 
lack critical regions of the linker and RING finger domains, while the intron 7 retention 
introduces a premature stop codon to abort translation upstream of the RING finger domain.
To investigate the functional properties of the variant mutant Cbl proteins encoded by 
homozygous point mutations, we first studied the effect of the common p.Y371H 
substitution on the growth of primary hematopoietic cells from murine fetal liver. This 
system reproduces the hypersensitivity to GM-CSF that is characteristic of JMML 16,29. 
Fetal liver cells transduced with retroviral vectors expressing wildtype or mutant Cbl 
proteins demonstrated no increased sensitivity to GM-CSF (Figure 3a). Similarly, 
expression of p.Y371H Cbl in a BaF3-EpoR cell line did not confer cytokine independence 
(Figure 3b). Based on the observation that JMML cells invariably lose the normal CBL allele 
and on recently published data21, we reasoned that reduction of normal Cbl expression 
might be mandatory to deregulate hematopoietic growth. Therefore, we introduced a short 
hairpin RNA, which markedly reduced the expression of murine Cbl in BaF3-EpoR cell 
lines (Figure 3c). We next transduced these cells with a series of wildtype and mutant 
human constructs and demonstrated strong expression of exogenous Cbl (Figure 3c). In this 
context, we observed cytokine independent proliferation (Figure 3d) upon expression of 
p.Y371H Cbl and a known murine oncogenic Cbl protein (70Z)30-32. The 70Z oncogenic 
protein deletes out 17 amino acids located from position 366-382 in the linker domain. 
Furthermore, the p.Y371H and 70Z transduced cells demonstrated hypersensitivity to 
increasing concentrations of human EPO (Figure 3e), mimicking the growth factor 
hypersensitivity seen in JMML (Figure 1d). In cells depleted of endogenous Cbl and 
expressing exogenous p.Y371H and 70Z Cbl proteins, we observed constitutive 
phosphorylation of ERK, AKT and S6 in cells deprived of cytokine. We also found 
heightened responses to low dose EPO (Figure 2f).
In order to determine if mutant Cbl proteins retain E3 ligase activity, we assessed their 
ability to promote ubiquitylation of a known Cbl substrate. Soon after activation, the 
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epidermal growth factor receptor (EGFR) undergoes Cbl-dependent polyubiquitylation and 
proteosomal degradation. HA-Cbl(p.Y371H)-expressing HEK293 cells exhibited markedly 
elevated levels of phosphorylated EGFR upon EGF stimulation in comparison to HA-
Cbl(WT)-expressing counterpart (Figure 4a), which indicates a possible defect in clearance 
of pEGFR by Cbl(p.Y371H). Cbl(p.C384R) mutant exhibited a similar defect in pEGFR 
clearance (data not shown). Upon polyubiquitylation of targets, Cbl promotes its own 
polyubiquitylation and subsequent auto-degradation. Consistent with this model, levels of 
Cbl(WT), but not Cbl(p.Y371H or p.C384R), rapidly diminished following EGF treatment 
in the absence of proteasome inhibitor MG132 (Figure 4a, b and data not shown,). However, 
Cbl(WT) levels were markedly stabilized in the presence of MG132 while Cbl(p.Y371H) 
levels remained relatively high irrespective of MG132 (Figure 4b), which suggest that Cbl 
mutants p.Y371H and p.C384R have an inherent defect in E3 function. Consistent with this 
notion, Cbl(WT) promoted robust polyubiquitylation of pEGFR while p.Y371H and 
p.C384R showed diminished capacity to polyubiquitylate pEGFR in an in vitro 
ubiquitylation assay (data not shown), similar to that of Cbl(70Z), which is known to be 
defective in E3 ligase activity, and in concordance with recently published data by Sanada et 
al 21, who demonstrated that p.Y371S and p.Q367P mutants detected in human patients also 
have diminished ubiquitylation activity. The Y371 residue most commonly affected in 
germline CBL mutations has been the focus of extensive biochemical analysis 21. This 
literature supports a key role for Y371 in maintaining the integrity of the alpha-helical 
structure of the linker region, which plays a critical role in substrate specificity. 
Interestingly, Y371 has been found to be phosphorylated despite its predicted location away 
from the protein surface. Substitution of this residue with phenylalanine results in a 
nononcogenic form of the protein, which lacks E3 ligase activity. Conversely substitution 
with a glutamate constitutively activates E3 ligase activity 33,34.
In most ways, CBL appears to function as a classic tumor suppressor gene in this cohort, 
with germline heterozygosity predisposing to neoplasia upon reduction to homozygosity in 
target tissues. However, the predominance of specific missense mutations makes CBL 
distinct from most tumor suppressor genes such as RB and NF1, which typically 
demonstrate more severe loss of function mutations such as deletion or protein truncation. 
This suggests that the mutant Cbl proteins retain an essential biochemical function 20,21. It is 
further supported by our data showing that exclusive expression of a mutant CBL allele has 
positive effects on cytokine signaling and proliferation. The specific disruption of E3 ligase 
activity may leave intact adapter functions, resulting in a relative imbalance of CBL's 
positive and negative roles in signal transduction. Sanada et al hypothesized that this may 
result in inhibitory effects on Cbl-b, a related family member21. This is similar to what has 
been reported for p53, a classic tumor suppressor gene with specific gain of function 
mutations in the context of loss of heterozygosity 35,36. Beyond missense mutations, 
truncated Cbl proteins are also known to confer transforming effects by countering the 
negative action of full-length Cbl on RTK signaling. The Drosophila analogue of the 
mammalian v-Cbl oncogene (i.e. Dv-Cbl), for example, functions as oncogenic dominant-
negative variant whose expression results in vivo in enhanced signaling of the EGFR 
cascade and cooperates with activating mutations in the Ras pathway to ultimately produce 
melanotic tumors 37.
Niemeyer et al. Page 5
Nat Genet. Author manuscript; available in PMC 2015 January 17.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
In addition, clinical data reveals that some patients may experience spontaneous resolution 
of JMML but go on to develop clinical features consistent with vasculitis and other 
autoimmune phenomena later in life. Interestingly, autoimmunity has also characterized 
genetically engineered mouse strains with Cbl mutations. Lck-Cre+ c-Cblflox/flox Cbl-b−/− 
mice, which delete c-Cbl in T cells, develop severe vascular lesions with massive infiltration 
of T-cells and high concentrations of anti-double stranded DNA antibodies 38. Furthermore, 
these T cells are hypersensitive to T cell receptor signaling and display prolonged ERK 
phosphorylation. Similarly, Cd19-Cre+ c-Cblflox/flox Cbl-b−/− mice that delete c-Cbl in B 
cells develop a lupus-like syndrome associated with perivascular infiltration and 
hyperactivation of B cell receptor signaling 39. In mice, loss of Cbl-b is required for these 
phenotypes. Oncogenic c-Cbl proteins thus may inhibit Cbl-b in vivo, resulting in a 
functional loss of both Cbl and Cbl-b, which in turn contributes to dysregulated lymphocyte 
signaling and subsequent vasculitis. Indeed, the redundant role of c-Cbl and Cbl-b was 
further explored by Sanada, et al, who demonstrated the inhibitory effects of c-Cbl p.Y371S 
on wildtype Cbl-b 21. It is of clinical interest that patients with JMML and homozygous CBL 
mutations who undergo HSCT are not known to develop vasculitis later in life, implying that 
a normal immune system is critical to preventing this late manifestation.
We describe a new syndrome in which affected children display several congenital 
anomalies that overlap with NF1, NS, and Legius, suggesting that the affected proteins 
converge on the Ras/MAPK pathway. Indeed, several Ras/MAPK pathway proteins regulate 
developmental programs in multiple species - for instance, the Drosophila homologs of each 
of these genes--CBL (D-cbl), PTPN11 (csw), NF1, and SPRED perform critical functions for 
growth and patterning 40-43.
Patients with germline CBL mutations are at increased risk of developing JMML, which 
may follow an aggressive clinical course or resolve without treatment. Some affected 
individuals develop vasculitis later in life. The CBL mutations found in JMML can arise de 
novo or can be transmitted through the germline, and human leukemia samples invariably 
show loss of the normal CBL allele. Consistent with this tumor suppressor function, JMML-
associated Cbl proteins confer cytokine hypersensitivity in transduced BaF3-EpoR cells in 
the absence of wildtype Cbl, have defective E3 ligase activity, and constitutively activate 
key Ras effector pathways. The role of aberrant Cbl signaling in vasculitis remains to be 
determined, and it will be particularly interesting to investigate if patients with germline 
CBL mutations who have been cured of JMML after HSCT remain at risk of developing 
vasculitis. It is also of great interest that some of these patients continue to display 
homozygous CBL mutations in their peripheral blood despite having improved their blood 
counts. Finally, our data provide strong evidence that Cbl is a key negative regulator of Ras 
signaling networks in hematopoietic cells and it will be important to identify key targets of 
the Cbl ubiquitin ligase and to uncover other biochemical mechanisms involved in growth 
control.
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METHODS
Subjects
Patients were diagnosed and treated either in Europe under the auspices of the European 
Working Group of Myelodysplastic Syndromes in Childhood (EWOG-MDS) or enrolled as 
research subjects at the University of California, San Francisco. The Committees on Human 
Research at each of the institutions in EWOG-MDS, as well as UCSF approved these 
studies. Informed consent was obtained from parents or guardians, and in the case of 
pedigree analysis, all screened relatives. Family and clinical histories were reviewed, as 
were physical exams at diagnosis.
Mutation Screening
Bone marrow or peripheral blood samples at diagnosis were obtained. Mononuclear cells 
were isolated using standard Histopaque 1111. Buccal swabs, fibroblasts, or tissues 
unaffected by tumor were also obtained when available. Genomic DNA was extracted using 
PureGene reagents (Qiagen, Foster City, CA). Patients were screened for mutations in CBL, 
NRAS, KRAS, and PTPN11 as previously described6,7,20.
RNA was prepared according to usual methods. cDNA was generated using the 
SuperScript® III First-Strand Synthesis System for RT-PCR (Invitrogen). Splice variants 
were identified through PCR using an annealing temperature of 58 °C and the following 
primers: 5’-TTGAGGGAACACATACTCGCT-3’ and 5’-
TATGTTACTGCTGATGGGAACA-3’. Splice variants were gel extracted using the 
QIAquick Gel Extraction Kit (Qiagen). The resulting fragments were subcloned using the 
TOPO® TA Cloning Kit (Invitrogen) according to the manufacturer's instructions. Positive 
colonies were picked, mini prepped using the QIAprep Spin Miniprep Kit (Qiagen), and 
sequenced with standard M13 Forward (-20) and M13 Reverse primers.
Cbl and shRNA expression constructs
For the CFU-GM experiments, Gateway technology (Invitrogen) was used to clone WT and 
mutant Cbl cDNAs into the murine stem cell virus (MSCV) backbone containing a green 
fluorescent protein (GFP) cassette driven by an internal ribosome entry site (IRES) 
downstream of the Cbl sequence (pMIG). The human WT and 70Z Cbl plasmids were a 
kind gift from Hamid Band 44. For the subsequent experiments using Ba/F3 cells, the same 
Cbl cDNAs were cloned into an MSCV-IRES-Venus (pMIV) backbone to allow for co-
transduction with the GFP-tagged shRNA. MiR30 based shRNA sequences targeting murine 
Cbl were graciously designed by Johannes Zuber and Scott Lowe. We selected one of these 
putative sequences (cbl.2364) and custom ordered a single 110-bp oligonucleotide (Bioneer) 
to serve as a template for PCR amplification. PCR products were digested with XhoI and 
EcoRI and ligated into the LTR-driven MiR30 SV40-GFP (LMS) MSCV-based vector (also 
graciously provided by the Lowe lab) to produce the LMS-2364 retrovirus encoding the Cbl 
shRNA. The sequence for cbl.2364 is 
TCGAGAAGGTATATTGCTGTTGACAGTGAGCGATACCTATGAAGCGATGTAT 
AATAGTGAAGCCACAGATGTATTATACATCGCTTCATAGGTACTGCCTACTG 
CCTCGG.
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Hematopoietic progenitor assays
All experimental procedures involving mice were reviewed and approved by the UCSF 
Committee on Animal Research. These assays were performed as described previously 
using murine fetal liver cells transduced with MSCV-Cbl-IRES-GFP retroviruses engineered 
to express WT or mutant Cbl proteins. For the human CFU-GM assays, mononuclear cells 
from peripheral blood or bone marrow were plated in MethoCult H4230 (StemCell 
Technologies), supplemented with recombinant human GM-CSF (Peprotech) and counted 
14 days later as described previously 28. For the CFU-GM assays, GFP-positive cells were 
sorted using a FACS Aria (BD Biosciences) and then seeded in methylcellulose medium 
(M3231; StemCell Technologies) 45, supplemented with recombinant murine GM-CSF 
(Peprotech). Colonies were counted by indirect microscopy after 8 days.
Cell Viability and Proliferation assays and Western blots
Murine pro-B Ba/F3 cells were transduced with MSCV-EpoR-IRES-puro as described 
previously 46. These cells were maintained in RPMI-1640 with 10% FCS (HyClone), 
penicillin, streptomycin, L-glutamine, 10 ng/ml puromycin (Calbiochem), and 10 µg/ml 
murine IL-3 (Peprotech).
The Ba/F3-EpoR cells were transduced with the LMS-2364 construct or the LMS vector 
alone. GFP-positive cells were sorted on a FACS Aria (BD Biosciences) and then 
transduced with the MSCV-Cbl-IRES-Venus retroviruses expressing WT or mutant Cbl 
proteins. Cells positive for both GFP and YFP expression were sorted on the FACS Aria and 
studied in proliferation and Western blot assays.
For the proliferation assays, cells were washed 3x and then cultured for 6 hours in cytokine-
free media before being plated in 6-well plates at a density of 500,000 cells/ml at increasing 
doses of hEPO (R&D Systems). Growth was monitored every other day using a ViCell cell 
counter (Beckman Coulter).
For Western blot analysis, cells were washed 3x and cultured for 6 hours in cytokine-free 
media before being stimulated for 15 minutes with increasing doses of hEPO (R&D 
Systems). Whole-cell lysates were blotted and probed with the following antibodies: anti-
phospho-p44/42 mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 
(ERK1/2) (Thr202/Tyr204, cat. 9101), anti-phospho-AKT (S473, cat. 4060), anti-phospho-
S6 (Ser235/236, cat. 2211) (all from Cell Signaling Technology); anti-phospho-STAT5 (cat. 
44-390G) (Invitrogen) and anti-alpha-tubulin (Abnova). ERK1/2 (cat. 9102), AKT (cat. 
9272), S6 (2217), and STAT5 (9363) antibodies were from Cell Signaling Technology.
HEKCells
HEK293 cells were obtained from the American Type Culture Collection (Rockville, MD) 
and maintained in Dulbecco's modified Eagle's medium supplemented with 10% heat-
inactivated fetal bovine serum (FBS) (Wisent, St. Bruno, QC, Canada) at 37°C in a 
humidified 5% CO2 atmosphere.
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Antibodies
Mouse monoclonal antibodies against HA (12CA5) and α-tubulin were obtained from 
Boehringer Ingelheim (Laval, QC, Canada) and Sigma (Milwaukee, WI), respectively. 
Rabbit polyclonal antibodies against pEGFR, EGFR and ubiquitin were obtained from 
Upstate (Temecula, CA), Santa Cruz Biotechnology (Santa Cruz, CA) and DAKO Canada 
(Mississauga, ON, Canada), respectively. EGF ligand was obtained from Sigma 
(Milwaukee, WI). MG132 proteasome inhibitor was obtained from Boston Biochem 
(Cambridge, MA).
Plasmids
Plasmids encoding HA-CBL(WT, 70Z, Y371H, C384R) were subcloned into the pcDNA-
DEST4.0 vector via Gateway Cloning technology (Invitrogen, Carlsbad, CA) and confirmed 
by DNA sequencing. Plasmid encoding EGFR was generated as previously described 47.
Immunoblotting and immunoprecipitation
Immunoprecipitation and immunoblotting were performed as described previously 48. Cells 
were lysed in EBC buffer (50mM Tris pH 8.0, 120mM NaCl and 0.5% NP-40) 
supplemented with protease and phosphatase inhibitors (Roche, Laval, QC, Canada). Cell 
lysates were immunoprecipitated with indicated antibodies in the presence of Protein-A 
agarose beads (Repligen, Waltham, MA). Bound proteins were washed five times with 
NETN buffer (20mM Tris pH 8.0, 120mM NaCl, 1mM EDTA, and 0.5% NP-40), eluted by 
boiling in sodium dodecyl sulfate (SDS)-containing sample buffer, and resolved by SDS-
polyacrylamide gel electrophoresis (PAGE).
In vitro ubiquitylation assay
In vitro ubiquitylation assay was performed as described previously 49.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Germline mutations in CBL can be inherited in an autosomal dominant fashion and 
are associated with a phenotype, GM-CSF hypersensitivity and vasculitis
Panel (a) demonstrates the angiograms from the aorta and left subclavian artery from patient 
D048 nine months after the diagnosis of Takayasu arteritis type III. Panel (b) The family 
tree of UPN1333 is shown in panel a, where the diseased bone marrow of UPN1333 
displayed a homozygous CBL c.1111T>C (red) mutation as well as a heterozygous lesion 
from his buccal swab (black). Only women appear to be heterozygote carriers, and only 
boys appear to be affected by JMML in this family. Panel (c) The bone marrow of UPN1125 
demonstrated a homozygous CBL mutation—her mother (III:5) is a known carrier, and she 
had two male cousins dying from JMML (III:6, III:7). Panel (d) demonstrates a classic GM-
CSF hypersensitivity response on a colony assay for patients with CBL mutations (n=3) 
versus normal (n=13). Error bars represent standard error of the mean (s.e.m.) Panel (e) 
shows one toddler (D703) diagnosed with JMML and a homozygous mutation at p.C384R. 
She displays frontal bossing, downslanting palpebral fissues, hypertelorism, and a low nasal 
bridge. Photographs of her father, who harbors a heterozygous mutation at p.C384R, are 
included in Figures S1, panel d. Of note, both father and daughter also display bilateral 
ptosis.
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Figure 2. Consequences of splice site mutations in cDNA from individuals D347, 647, and I066
Panel (a) RT-PCR using an exon 6 forward primer and an exon 10 reverse primer on cDNA 
generated from these patients. The wildtype amplicon is 616 base pairs long. Lane 1: MW 
ladder, Lane 2: I066, Lane 3: D347, Lane 4: D647, Lane 5: CBL point mutant, Lane 6: 
HM2833 CBL wildtype, Lane 7: Genomic DNA control, Lane 8: no template control. Panel 
(b) is a schematic representation of the splice site variants detected either recurrently (D347) 
or that were shared by I066 and D647. Sequences are shown in Figure S2. Deletions of base 
pairs are indicated by Δ# of base pairs and insertions by ins # base pairs. Premature stop 
codons are indicated by asterisks (*).
Niemeyer et al. Page 14
Nat Genet. Author manuscript; available in PMC 2015 January 17.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 3. p.Y371H does not confer cytokine sensitivity or cytokine independent growth until 
silencing of murine Cbl
Panel (a) Transduction of p.Y371H or the known murine oncogeneic mutant 70Z in 
wildtype hematopoietic cells from fetal liver, did not confer hypersensitivity to GM-CSF, 
nor did expression of these mutants in BaF3-EpoR cells result in cytokine independent 
growth (b). Panel (c) An shRNA to murine Cbl (cbl.2364) demonstrated near complete 
shutdown of expression in BaF3-EpoR cells by Western blot with re-expression upon 
introduction of the human WT, 70Z, or p.Y371H in these same cell lines. Panel (d) Both the 
p.Y371H and 70Z Cbl conferred cytokine independent growth in the presence of cbl.2364. 
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Controls included the Venus vector pMIV and BaF3-EpoR. Error bars for triplicate 
replicates (s.e.m.) are shown and when not visible, indicate tight clustering. Using a paired t-
test: day 7 comparing 2364+ WT-Cbl versus 2364+p.Y371H, p-value= 0.017, and at day 9: 
p-value <0.001. Panel (e) Serial transduction of the hairpin (2364) and p.Y371H or 70Z 
constructs also conferred hypersensitive growth after assessing cell proliferation on day 5 in 
increasing concentrations of Epo. Using a paired t-test at each concentration of Epo when 
comparing 2364+WT-Cbl versus 2364+p.Y371H: Epo 0 unit/ml: p = 0.036, Epo 0.01 
units/ml: p= 0.0015, Epo 0.1 units/ml: p= 0.029, Epo 1 unit/ml (saturating dose) P= 0.697. 
Panel (f) Both the p.Y371H and 70Z containing cells demonstrated activation of pERK, 
pAKT, and pS6 in the absence of Epo or in low dose 0.01 unit/mL of Epo in comparison to 
negative controls. All cell proliferation work was done in triplicate.
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Figure 4. Cbl mutant proteins exhibit prolonged protein turnover and are associated with 
increased phosphorylated EGFR levels upon EGF stimulation
Panel (a) HEK293 cells transfected with plasmids encoding EGFR in combination with HA-
Cbl(WT) or HA Cbl(p.Y371H) were serum starved for 18 h followed by 15 min EGF (50 
ng/ml) stimulation. Cells were then washed and maintained in serum-free media for the 
indicated periods of time. Equal amounts of whole cell extracts were resolved on SDS-
PAGE and immunoblotted with the indicated antibodies. Panel (b) HEK293 cells transfected 
with plasmids encoding EGFR in combination with HA-Cbl(WT) or HA-Cbl(p.Y371H) 
were serum starved for 18 h followed by 15 min EGF (50 ng/ml) stimulation. Cells were 
then washed and maintained in serum-free media with (+) or without (-) MG132 for the 
indicated periods of time. Equal amounts of whole cell extracts were resolved on SDS-
PAGE and immunoblotted with the indicated antibodies.
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